Stay updated on Pembrolizumab with Chemotherapy in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab with Chemotherapy in Endometrial Cancer Clinical Trial page.

Latest updates to the Pembrolizumab with Chemotherapy in Endometrial Cancer Clinical Trial page
- Check4 days agoChange DetectedThe page now displays the ClinicalTrials.gov record for the endometrial cancer study, including its treatment arms, eligibility criteria, results, locations, and study documents.SummaryDifference100%

- Check11 days agoChange DetectedThe footer's ClinicalTrials.gov revision label changed from v3.7.2 to v3.8.0. The page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check25 days agoChange DetectedA sitewide NIH notice about a terminology transition appears above the page, and the site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check39 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check53 days agoChange DetectedAccess to the study record now displays a 403 Forbidden error page instead of the study content. The page header shows 403 Forbidden and includes a Home link, indicating an access restriction rather than the study details being shown.SummaryDifference18%

- Check60 days agoChange DetectedThe page's revision tag was updated to v3.7.0, replacing the previous v3.6.6 in the site's revision history.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab with Chemotherapy in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with Chemotherapy in Endometrial Cancer Clinical Trial page.